Evaluation of the Samsung LABGEO PT10 Hepatic Panel in a Point-of-Care Setting
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
Oregon
-
Portland, Oregon, United States, 97239
- Oregon Health & Science University
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Male or female subjects with a history of elevated liver enzymes or symptoms suggestive of elevated liver enzymes
- Presenting to the site and requiring testing for levels of liver enzymes as part of routine care at the site
- Subjects able and willing to provide written informed consent
Exclusion Criteria:
- Subjects unable or unwilling to provide written informed consent
- Subjects with a life-threatening disease or any serious, potentially life-threatening medical illness that may compromise patient safety or study conduct
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
symptoms of liver disease
Device: Samsung LABGEO PT10 Hepatic Panel
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Bias between Samsung LABGEO PT10 serum results and matching FDA-cleared comparator assay
Time Frame: baseline
|
baseline
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Mean percentage difference between all pairs of plasma and serum measurements using Bland-Altman plot of differences.
Time Frame: baseline
|
baseline
|
|
Standard deviation and coefficients of variation of between run, between day and total precision.
Time Frame: 20 days
|
20 days
|
|
Estimates of reference intervals by computing the 2.5th percentile of associated distribution of test measurement (for each analyte) and the 97.5th percentile of associated distribution.
Time Frame: baseline
|
baseline
|
|
Mean percentage difference between all pairs of serum and whole blood measurements using Bland-Altman plot of differences.
Time Frame: baseline
|
baseline
|
|
Mean percentage difference between all pairs of plasma and whole blood measurements using Bland-Altman plot of differences.
Time Frame: baseline
|
baseline
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Chair: Nam Shin, Nexus DX
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- T10-02
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.